using bcma-targeting agents in earlier lines of treatment for multiple myeloma
Published 1 year ago • 98 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
2:31
integrating bcma-targeted agents in earlier lines of therapy for r/r multiple myeloma
-
0:53
incorporating bcma-targeted car-t therapy in the frontline treatment of multiple myeloma
-
2:31
the value of bcma-targeting therapy in multiple myeloma: current applications and future outlooks
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
2:19
sequencing bcma-targeted agents in multiple myeloma
-
1:48
mechanisms behind the loss of bcma in multiple myeloma & options for patients
-
1:29
sequencing bcma-targeted therapies in myeloma
-
0:50
how can bcma be used as a target for mutiple myeloma treatment?
-
1:30
managing the challenges associated with continuous bcma-directed therapy in multiple myeloma
-
1:47
role of bcma-targeting adcs in the management of myeloma
-
2:53
novel targets and dual-targeting approaches in myeloma
-
1:29
improving outcomes of bcma-targeting adcs in multiple myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
1:45
targetting bcma in myeloma
-
1:37
integrating bcma-targeted immunotherapies into challenging multiple myeloma cases
-
1:24
disparities in access and practice patterns of bcma-directed therapies in multiple myeloma
-
1:02
managing progression after bcma-targeted therapy in r/r multiple myeloma
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma